Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have been given an average rating of “Moderate Buy” by the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.75.

Several analysts recently commented on SNTI shares. Wall Street Zen lowered shares of Senti Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. HC Wainwright assumed coverage on shares of Senti Biosciences in a research note on Tuesday, October 14th. They issued a “buy” rating and a $12.00 target price for the company. Leerink Partners began coverage on Senti Biosciences in a research note on Friday. They issued an “outperform” rating and a $6.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Senti Biosciences in a report on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI traded down $0.03 during mid-day trading on Friday, hitting $1.78. The company had a trading volume of 52,445 shares, compared to its average volume of 175,109. Senti Biosciences has a 12 month low of $1.26 and a 12 month high of $16.94. The stock has a market cap of $46.80 million, a price-to-earnings ratio of -0.53 and a beta of 2.09. The firm’s 50 day simple moving average is $1.76 and its two-hundred day simple moving average is $2.09.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). Equities analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current year.

Hedge Funds Weigh In On Senti Biosciences

A number of hedge funds have recently made changes to their positions in SNTI. Armistice Capital LLC bought a new position in shares of Senti Biosciences during the 2nd quarter worth about $1,883,000. Nantahala Capital Management LLC bought a new position in shares of Senti Biosciences during the 1st quarter worth approximately $2,984,000. Heights Capital Management Inc. bought a new stake in Senti Biosciences in the first quarter valued at $2,520,000. Geode Capital Management LLC grew its position in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Senti Biosciences during the third quarter valued at $117,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.